The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Biogen Inc stock forecast from 16 analysts, the average analyst target price for Biogen Inc is USD 274.54 over the next 12 months. Biogen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biogen Inc is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Biogen Inc’s stock price was USD 200.81. Biogen Inc’s stock price has changed by -1.93% over the past week, +0.34% over the past month and -23.16% over the last year.
No recent analyst target price found for Biogen Inc
No recent average analyst rating found for Biogen Inc
Company Overview Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Read Less
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for mu...Read More
Frequently Asked Questions About Biogen Inc (BIIB) Stock
Based on ratings from 16 analysts Biogen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 25 buy, sell and 10 hold ratings.
Unfortunately we do not have enough data on BIIB's stock to indicate if its a good dividend stock.
Based on targets from 16 analysts, the average taret price for BIIB is USD 274.54 over the next 12 months. The maximum analyst target price is USD 342 while the minimum anlayst target price is USD 190.
BIIB stock's Price/Earning ratio is 25.84.
Our analysis grades BIIB stock's Price / Earning ratio at A+. This means that BIIB stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this BIIB may be undervalued for its sector.
The last closing price of BIIB's stock was USD 200.81.
The most recent market capitalization for BIIB is USD 29.85B.
Based on targets from 16 analysts, the average taret price for BIIB is projected at USD 274.54 over the next 12 months.
This means that BIIB's stock price may go up by +36.72% over the next 12 months.
We can't find any ETFs which contains Biogen Inc's stock.
As per our most recent records Biogen Inc has 7,570 Employees.
Biogen Inc's registered address is 225 Binney Street, Cambridge, MA, United States, 02142.
You can get more information about it from Biogen Inc's website at https://www.biogen.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Biogen Inc (BIIB) Stock
Based on ratings from 16 analysts Biogen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 25 buy, sell and 10 hold ratings.
Unfortunately we do not have enough data on BIIB's stock to indicate if its a good dividend stock.
Based on targets from 16 analysts, the average taret price for BIIB is USD 274.54 over the next 12 months. The maximum analyst target price is USD 342 while the minimum anlayst target price is USD 190.
BIIB stock's Price/Earning ratio is 25.84.
Our analysis grades BIIB stock's Price / Earning ratio at A+. This means that BIIB stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this BIIB may be undervalued for its sector.
The last closing price of BIIB's stock was USD 200.81.
The most recent market capitalization for BIIB is USD 29.85B.
Based on targets from 16 analysts, the average taret price for BIIB is projected at USD 274.54 over the next 12 months.
This means that BIIB's stock price may go up by +36.72% over the next 12 months.
We can't find any ETFs which contains Biogen Inc's stock.
As per our most recent records Biogen Inc has 7,570 Employees.
Biogen Inc's registered address is 225 Binney Street, Cambridge, MA, United States, 02142.
You can get more information about it from Biogen Inc's website at https://www.biogen.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIIB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
